<qa>  What is the name of the antagonist that has been shown to reduce fibrosis pre-Galectin-3 contributes to fibrosis, is elevated in patients with ESRD, and correlates with adverse outcomes de Boer et. al., 2011, Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008. Animal models with genetic knockout of galectin-3 demonstrate a reduction in structural and functional deficits in the kidney Dang et. al., 2012, Fernandes Bertocchi et. al., 2008, Henderson et. al., 2008. GCS-100 is a galectin-3 antagonist that has been shown to reduce fibrosis pre-clinically. Based on the role of galectin-3 and fibrosis in kidney disease, the Sponsor believes GCS-100 may be effective at treating patients with CKD. 